Merck Strengthens Immunology Pipeline with Prometheus Acquisition…
PRA023 is a novel candidate for late-stage ulcerative colitis and Crohn’s disease and other autoimmune diseases Prometheus Biosciences’ comprehensive data set enables target discovery and